Related Experiment Video
Updated: Jun 24, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
A long-term follow-up of botulinum toxin A in cervical dystonia
B Mohammadi1, N Buhr, H Bigalke
1Department of Neurology and Clinical Neurophysiology, Hannover Medical School, Hannover, Germany. mohammadi.bahram@mh-hannover.de
Objective:
Cervical dystonia (CD) is the most common form of adult-onset focal dystonia, and botulinum toxin A (BoNT-A) has become the first-line treatment for this condition.
Methods:
In this work, we present data of 207 CD patients treated with BoNT-A for 6.7 +/- 3.5 years. One hundred and sixty-three patients were treated with Dysport (mean dose, 389 +/- 144 U) and 44 with Botox (mean dose, 145 +/- 44 U).
Results:
The mean clinical benefit, based on a 0-3 scale (0=no effect, 1=slight, 2=moderate and 3=marked improvement) was similar for Dysport (2.5 +/- 0.3) and Botox (2.2 +/- 0.4). Adverse events were mild and similar for both products. Fewer than 2% of the patients developed neutralizing antibodies.
Discussion:
These data confirm the efficacy and safety of BoNT-A treatment in CD over an extended period of up to 14 years.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Botulism
Tetanus
Skeletal Muscle Relaxants: Therapeutic Uses
Depolarizing Blockers: Pharmocokinetics
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
